Chembio Diagnostics, Inc. (OTC Bulletin Board: CEMI) has entered a development agreement for up to about $900,000 in connection with the development and initial supply of a multiplex rapid point of care influenza immunity test. The test will use Chembio's patented Dual Path Platform technology. The agreement contemplates an approximate 9 month period in which the development is to be finished within.
MicroCap Insider is a web-based financial portal.
Sign Up for our Free Stock Newsletter
MicroCap Insider publishes a free penny stock newsletter providing stock alerts on companies positioned to deliver high-yield gains to investors.
The objective of the project is to develop a product that is able to determine an immunity to seasonal and novel influenza viruses. The test will have 6 different parameters plus a control line on a single POC DPP device.
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA approved rapid HIV tests are marketed in the U.S. by Inverness Medical Innovations, Inc. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through partnerships and distributors.
Sign Up for FREE. Investors interested in receiving small cap stock alerts through the penny stock newsletter published by MicroCap Insider can sign up for free by visiting our website.
About Us
MicroCap Insider is a leading penny stock web site with extensive experience in the OTC market, providing top stock picks, investing tips and exclusive research on small cap stocks on the verge of producing large financial gains.
Please click here to read the full disclaimer.
